Demand for generics keeps soaring


Zagreb – Consolidation of the generic-drug business is focusing on eastern Europe. So far in 2006, at least eight deals have been announced, including Barr Pharmaceuticals‘ US$2.5-billion acquisition of Croatia‘s Pliva, completed at the end of October. Generic-drug makers are caught between soaring demand and falling prices. At the same time, competition from low-cost players in India and China is intensifying as they shift from supplying only raw materials to actual manufacturing. As a result, generics players are losing their sources of cheap ingredients and gaining a new competitors in the process.
So why is big pharma heading east? Demand for generic drugs in Russia, for instance, is growing between 30% and 40% a year, compared with 7% in the U.S. Another big attraction: the dominance of so-called ‘branded generics’. These copies of off-patent prescription drugs are marketed under brand names and sell for more than commodity generics. While consumers in the region can’t afford high-priced brand-name formulas, they are willing to pay more for the perceived higher quality associated with branded generics.
Pliva also excels at what is perceived as the next big frontier in the pharma business: biosimilars, or off-patent versions of genetically engineered biotech drugs. Moreover, the deal gives Barr better access to Central and Eastern Europe and Russia.
Barr isn‘t the only active player in the region. Novartis‘ Sandoz, the world‘s second-largest generics maker by sales, bought Slovenia‘s Lek four years ago. Over the past two years, Actavis has snapped up eastern European generics makers, including Hungary‘s Kéri Pharma, Bulgaria‘s Higia, the Czech Republic‘s Pharma Avalanche, and Romania‘s Sindan. In March, French Sanofi-Aventis paid US$565 million for a 25%-stake in Czech Zentiva. Even Indian players are getting in on the action: In March, Ranbaxy spent US$374 million for a majority in Terapia, Romania‘s largest generic company.
Next up: Slovenia’s Krka is one possible target, although its US$2 billion-plus market cap is likely to attract only deep-pocket players. Another possible target is Hungary‘s Gedeon Richter, the No. 1 generics player in Russia. With operating margins of 28% and a lucrative niche in women’s health, Gedeon Richter is expected to post annual sales growth in excess of 15% through to 2010. Poland‘s biggest generics company, Pol­pharma, might also be in play, and the rest of Zentiva could also be up for grabs.



Zagreb - Croatia's Government passed a new law on genetically modified organisms (GMO), which replaces the “biotechnology-regulating provisions” of the Law on the Protection of Nature that up to now regulated the importation,...



Ljubljana - Slovenian pharma company Pharmaswiss and Swiss pharma group Helsinn Healthcare SA have signed a licensing agreement granting Pharma-swiss the exclusive license and distribution rights for ALOXI®, a strong and...



Brac - The “Fall 2005 Course on Bioprocess Engineering”, organized by the EFB's Working Group on Bioreactor Performance in collaboration with the European Section on Biochemical Engineering Science, will be held from September...



Zagreb - The 4th International Conference on “Biotechnology and Immunomodulatory Drugs” will open its gates from February 20-23, 2005, in Zagreb, Croatia. Organized amongst others by the Croatian Society of Biotechnology and...



Ljubljana - Slovenia's supreme court has rejected an appeal by US-drug group Merck & Co. Inc. in August, ending a 10-year patent dispute with local drug maker Krka d.d. over one of its best-selling drug. The court rejected a...



Opatija - Nutrition-related biotechnology has been subject to many controverse public debates lately. The organizers of the “2nd Central European Meeting - 5th Croatian Congress of Food Technologists, Biotechnologists und...



Ljubljana - BIA Separations, specialized in the short monolithic column technology, will hold the “First Summer School on Monoliths for Biochro-matography, Bioconversion, and So-lid Phase Synthesis” in Potoroz, Slo-venia, from...



Menges - Lek Pharmaceuticals inaugurated a new manufacturing plant (PORT1) for the production of biopharmaceuticals - such as human proteins for therapeutic applications - near the Slovenian capital Lubljana in Menges in early...



Ljubljana - Slovenian pharmaceutical company Lek d.d. successfully defended in late December its patent EP 1 095 037, which covers Lek's synthesis of Ome-prazole before the Board of Appeal of the European Patent Office....



Ljubljana - Scientists at the Department of Biochemistry and Molecular Biology, Jozef Stefan Institute, Ljubljana, have identified an intracellular membrane receptor for a snake venom secretory phospholipase A (sPLA). The...

Displaying results 11 to 20 out of 22

< Previous 11-20 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%


  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%


  • 4SC1.18 EUR71.0%
  • MEDIGENE12.90 EUR63.9%
  • FORMYCON31.00 EUR31.1%


  • MORPHOSYS60.74 EUR-13.0%
  • BB BIOTECH281.20 EUR-11.2%
  • EPIGENOMICS5.31 EUR-10.6%


  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%


  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 18.04.2015

Current issue

All issues